Abbott Laboratories Announces Impressive Q4 2024 Financial Results

Abbott Laboratories has reported a significant 7.2% increase in sales for the fourth quarter of 2024, totaling $11 billion. This growth, although slightly below the anticipated $11.03 billion consensus, marks a notable achievement for the healthcare giant.

Net Earnings and EPS Experience Dramatic Rise

The company's net earnings saw an extraordinary surge, increasing by 479% to $9.2 billion. Similarly, diluted earnings per share (EPS) also witnessed a remarkable 479% jump, reaching $5.27. These figures underscore Abbott Labs' robust financial health and operational efficiency.

2024 Full-Year Performance Highlights

For the entire year of 2024, Abbott Labs achieved a revenue milestone of $42 billion, reflecting a 4.6% increase from the previous year. The net profit for the year soared by 134% to $13.4 billion, with diluted EPS also rising by 134% to $7.64 annually.

Looking Ahead: 2025 Projections and Dividend Announcement

Looking forward, Abbott Labs has set its 2025 diluted EPS expectations between $5.05 and $5.25, with an organic sales growth forecast of 7.5% to 8.5%. Additionally, the company has declared a quarterly dividend of $0.59 per share, scheduled for payment on February 14. Following the earnings report, Abbott Labs' shares experienced a 2.92% increase in premarket trading.